Pfisterer M, Teetzmann A, Vetter S, Baeßler J, Schreckenberger L, Zaiser J, Stenger M, Bach P. CBD attenuates amygdala response to negative emotional stimuli in individuals with alcohol use disorder - a randomized controlled trial. Psychopharmacology (Berl). 2025 Aug 29. [Epub ahead of print]
Pfisterer M, Zimmermann S, Zaiser J, Gerhardt S, Vollstädt-Klein S, Kiefer F, Bach P. Biomarkers in alcohol use disorder - the promise and pitfalls of neuroimaging drug cue reactivity. Biomarkers in neuropsychiatry. 2025 12:100119.
Vetter S, Weinberg J, Thomas BC, Kirchner M, Thalmann P, Klose C, Pfisterer M, Kölsch T, Oesterle S, Vollstädt-Klein S, Koopmann A, Lenz B, Kiefer F, Link T, Bach P. Investigation of the combined effects of cannabidiol plus naltrexone on alcohol craving in alcohol dependence: study protocol of a phase II randomised, double-blind, placebo-controlled, parallel-group trial - ICONICplus Trial. BMJ Open. 2025 15(8):e106348.
Zimmermann S, Teetzmann A, Baeßler J, Schreckenberger L, Zaiser J, Pfisterer M, Stenger M, Bach P. Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial. Mol Psychiatry. 2025 30(6):2612-2619. Epub 2024 Dec 12.